The U.S. Food and Drug Administration (FDA) has reported positive results in its Phase 2a trial of an oral insulin capsule produced by Israeli-based Oramed. The drug is for the treatment of Type 2 diabetes.
The Phase 2b study will be carried out later this year, and Oramed also plans a Phase 2a study for Type 1 diabetes.
Oramed’s stock jumped nearly 10 percent in NASDAQ trading in New York on Wednesday in after-hours trading following the announcement of the results of the trial.
“We are extremely pleased with the results, which give a solid validation for Oramed’s platform technology in general and our oral insulin program in particular,” said Nadav Kidron, Oramed’s chief executive.
About the Author: JewishPress.com brings you the latest in Jewish news from around the world. Stay up to date by following up on Facebook and Twitter. Do you have something noteworthy to report? Submit your news story to us here.
If you don't see your comment after publishing it, refresh the page.
Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.
If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.